首页> 外文期刊>Bone marrow transplantation >Use of idarubicin in pre-transplant conditioning in children with high-risk acute leukaemia.
【24h】

Use of idarubicin in pre-transplant conditioning in children with high-risk acute leukaemia.

机译:伊达比星在高危急性白血病儿童移植前调理中的应用。

获取原文
获取原文并翻译 | 示例
       

摘要

The major cause of treatment failure following allogeneic bone marrow transplantation for acute leukaemia is disease relapse. In an attempt to reduce post- transplant relapse in 33 children with high-risk acute leukaemia who received a related or unrelated bone marrow transplant, the pre-transplant conditioning regimen was intensified by the addition of idarubicin. Its toxicity and effects on survival were evaluated over a 57-month period. Toxicity, largely gastrointestinal, was increased but acceptable, and there was no specific regimen-related toxicity. Relapse rates were low (24%) in this high risk group, but mortality was increased in those receiving unrelated donor grafts, largely due to sepsis. Idarubicin does appear to have a role to play in the conditioning regimen of patients with high-risk acute leukaemia undergoing BMT, and may reduce relapse rates without increasing transplant-related mortality.
机译:同种异体骨髓移植治疗急性白血病后治疗失败的主要原因是疾病复发。为了减少33名接受相关或不相关骨髓移植的高危急性白血病儿童的移植后复发,通过添加伊达比星加强了移植前的调理方案。在57个月内评估了其毒性和对生存的影响。毒性(主要是胃肠道)增加但可以接受,并且没有与治疗方案相关的特异性毒性。在这个高风险组中,复发率很低(24%),但是接受无关移植的人死亡率增加了,主要是由于败血症。依达比星似乎在接受BMT的高危急性白血病患者的调理方案中起着作用,并且可以降低复发率而不增加与移植相关的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号